Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Payables (2016 - 2025)

Historic Payables for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $16.2 million.

  • Usana Health Sciences' Payables rose 13035.08% to $16.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 13035.08%. This contributed to the annual value of $12.0 million for FY2024, which is 1900.7% up from last year.
  • According to the latest figures from Q3 2025, Usana Health Sciences' Payables is $16.2 million, which was up 13035.08% from $17.9 million recorded in Q2 2025.
  • Usana Health Sciences' 5-year Payables high stood at $18.2 million for Q1 2021, and its period low was $6.6 million during Q2 2024.
  • Its 5-year average for Payables is $11.7 million, with a median of $11.1 million in 2022.
  • In the last 5 years, Usana Health Sciences' Payables crashed by 2830.8% in 2024 and then surged by 16923.89% in 2025.
  • Over the past 5 years, Usana Health Sciences' Payables (Quarter) stood at $13.7 million in 2021, then fell by 19.39% to $11.0 million in 2022, then decreased by 8.86% to $10.1 million in 2023, then rose by 19.01% to $12.0 million in 2024, then skyrocketed by 35.34% to $16.2 million in 2025.
  • Its Payables was $16.2 million in Q3 2025, compared to $17.9 million in Q2 2025 and $14.0 million in Q1 2025.